Vanguard Capital Management
FDMT icon

Vanguard Capital Management’s 4D Molecular Therapeutics FDMT Stock Holding History

Vanguard Capital Management’s Portfolio FDMT Stock Details FDMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$27.9M Sell
2,099,055
-96,523
-4% -$940K ﹤0.01% 2270
2026
Q1 		$20.4M Buy
+2,195,578
New +$19.1M ﹤0.01% 2336

Other funds holding FDMT

JT
Jupiter Topco New York $245B AUM
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM

Vanguard Capital Management's FDMT Position: Q2 2026 in Review

Vanguard Capital Management reduced its 4D Molecular Therapeutics (FDMT) stake by 4.4% in Q2 2026, selling an estimated $940K and leaving 2,099,055 shares worth $27.9M. The position accounts for ﹤0.01% of the portfolio, ranked #2270.

Vanguard Capital Management first reported a position in FDMT in Q1 2026 and has held it in 2 quarters since. 158 funds tracked by Wall St. Rank hold FDMT as of Q2 2026.

  • Vanguard Capital Management held 2,099,055 shares of 4D Molecular Therapeutics worth $27.9M as of Q2 2026.
  • Vanguard Capital Management sold 96,523 4D Molecular Therapeutics shares in Q2 2026, an estimated $940K.
  • 4D Molecular Therapeutics made up ﹤0.01% of Vanguard Capital Management's portfolio in Q2 2026, its #2270 holding.
  • Vanguard Capital Management first reported a position in 4D Molecular Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 158 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q2 2026.

Based on Vanguard Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.